On Aug. 19, 2020, Bio-Techne in partnership with Leica Biosystems, announced the automation of RNAscope COVID-19 probes on BOND RX*, Leica’s staining platform, for research use only. Researchers now have the ability to automate their COVID-19 research protocols, reducing manual labor and turnaround time.

The BOND RX is a flexible, open platform with the capability to run Bio-Techne RNAscope™ (duplex and multiplex) protocols, allowing for boundless innovation.

The RNAscope™ probes are designed to detect SARS-Cov-2 viral RNA, SARS-Cov-2 viral replication sequences, and cellular receptors targeted by the virus, including ACE2 and TMPRSS2.

Bio-Techneis a leading developer and manufacturer of high-quality purified proteins and reagent solutions – notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne’s product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments.

Leica Biosystems (LeicaBiosystems.com) is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology.